Integra LifeSciences shares likely to climb further, says Oppenheimer After meeting with Integra's CEO, Oppenheimer expects the stock to rise into the company's analyst day on October 24, when it is expected to announce more details about its cost saving plans. The firm expects the company's operating margin to increase, and it raised its target on the shares to $46 from $42 while maintaining an Outperform rating.
News For IART From The Last 14 Days
Check below for free stories on IART the last two weeks.
Subscribe for More Information